Browse

Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
Kim, Su-Jung; Han, Sae-Won; Oh, Do-Youn; Yi, Nam-Joon; Im, Seock-Ah; Kang, Gyeong Hoon; Bang, Yung-Jue; Kim, Tae-You; Jang, Ja-Joon; Suh, Kyung Suk; Yoon, Jung-Hwan; Kim, Yoon Jun
Issue Date
2010-12
Publisher
INT INST ANTICANCER RESEARCH
Citation
ANTICANCER RESEARCH; Vol.30 12; 5245-5250
Keywords
Chemotherapyplatinumhepatocellular carcinomaS-1
Abstract
Background: Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other flouropyrimidines against tumors with higher DPD activity, such as hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively investigated the efficacy of S-1 and platinum in HCC. Patients received S-1 (80 mg/m(2)/day on days 1-14) with either cisplatin (60 mg/m(2) on day 1) or oxaliplatin (130 mg/m2 on day 1) every 3 weeks. The primary end point was overall response rate. Results: Among the 21 HCC patients, 12 and 9 patients received S-1-based chemotherapy as a first-line and salvage treatment, respectively. Partial response was seen in 5 patients and stable disease in 6. The median time-to-progression was 4.0 months (95% confidence interval [CI], 2.4-5.6) and median overall survival was 14.0 months (95% CI, 6.7-21.3). Most patients were tolerable to chemotherapy and no grade 4 toxicity was observed. Tumors with lower DPD expression were more responsive to the therapy (response rate 60.0% in lower vs. 0.0% in higher DPD, p=0.045). Conclusion: S-1 and platinum combination chemotherapy shows favorable efficacy and tolerability in advanced HCC.
ISSN
0250-7005
Language
English
URI
http://hdl.handle.net/10371/77445
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse